Nasal antibody helps Long COVID mice
A new preprint reports that a nasal anti‑CD3 monoclonal antibody reduced neuroinflammation in a Long COVID mouse model, offering an immune‑targeting approach rather than a broad antiviral treatment. (x.com) The study found effects even when the treatment was given four weeks after infection, which is promising preclinical evidence but still a long way from proving safety or efficacy in people. (x.com)
Long COVID often looks less like a virus that never left and more like a fire alarm that never turned off. In a mouse study posted on April 7, 2026, researchers tested whether calming the immune system inside the nose could quiet lingering brain inflammation after a mild SARS-CoV-2 infection. (biorxiv.org) The treatment is an anti-CD3 monoclonal antibody, which is a lab-made protein that grabs onto CD3, a switch on T cells. T cells are the immune system’s field officers, so touching that switch can change how loudly they respond instead of trying to kill the virus directly. (frontiersin.org) The nose matters because it is one of the shortest routes to immune tissue connected to the head. Earlier work from the same research orbit found that nasal anti-CD3 could generate regulatory T cells, which are immune cells that act more like referees than fighters. (nature.com) In the new preprint, the mice were not given a severe pneumonia model. The team used a respiratory-restricted mild SARS-CoV-2 infection designed to mimic the kind of post-infection brain symptoms seen in Long COVID rather than acute organ failure. (biorxiv.org) After infection, untreated mice showed gliosis in white matter and the hippocampus. Gliosis is the brain’s version of a neighborhood staying on emergency footing, with support cells remaining activated long after the original damage. (biorxiv.org) The support cells here were microglia and astrocytes. Microglia are the brain’s resident immune sentries, and astrocytes are helper cells that keep neurons supplied and stable, but both can become part of the problem when they stay stuck in inflammatory mode. (biorxiv.org) Mice that got the nasal antibody had more FoxP3-positive, interleukin-10-positive regulatory T cells in the brain. Interleukin-10 is a calming signal, and the study linked that signal to less activation of microglia and astrocytes, more neurogenesis in the hippocampus, and better short-term memory performance. (biorxiv.org) The timing is one reason people noticed the paper. The antibody helped not only when given soon after infection, but also when given four weeks later, after chronic neuroinflammation was already established in the mice. (biorxiv.org) The team also reported that the treatment shifted microglia away from an inflammatory program driven by nuclear factor kappa B, which is a gene-control pathway cells use to crank up immune responses. In its place, the microglia showed more signals linked to chemokines, phagosomes, and transforming growth factor beta, which points to a more regulatory cleanup state. (biorxiv.org) There was one human clue in the paper, but it was small and indirect. Patients with neurological Long COVID had lower circulating regulatory T cell populations, which fits the mouse result but does not show that the nasal antibody will fix symptoms in people. (biorxiv.org) That gap matters because this is still a preprint, which means no peer review yet, and mouse cognition studies do not reliably predict human benefit. The best human evidence for this drug class so far is a 39-patient pilot study in mild to moderate COVID-19 in 2021 that reported the nasal antibody was well tolerated and was associated with lower inflammatory markers and faster clearing of lung infiltrates, not treatment of Long COVID brain symptoms. (biorxiv.org) (frontiersin.org) So the real news is not that Long COVID now has a nasal cure. The real news is that one preclinical study points to a different target entirely: not the virus itself, but the immune cells that may keep the brain’s alarm system ringing weeks after infection. (biorxiv.org)
